All In Biotech

Drug Trial Radar · NCT06840769

A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers

A Phase I, Open Label, Single Dose, Two Parts Study in Male and Female Healthy Subjects to Assess the Safety and Pharmacokinetics of Fosnetupitant 235 mg Administered as IV Bolus and of Derived Netupitant and Netupitant Metabolites

Last checked: Nov 20, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

50

Actual

Start

Jun 17, 2023

Primary completion

Oct 18, 2023

Study completion Oct 23, 2023

Sponsor

Lead sponsor
Helsinn Healthcare SAIndustry
Sponsor type
Industry
First posted
Feb 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial will include two parts, i.e., Part A and Part B. The goal of the Part A is to define the shortest safe and tolerable duration of an intravenous injection of Fosnetupitant 235 mg solution among 4 durations tested in male and female adult healthy volunteers. In study part A, researchers will compare Fosnetupitant 235 mg solution to Akynzeo® solution. The duration determined in Part A will be investigated in study Part B. The Part B of the study was not performed.

Conditions

  • Healthy Volunteers

Interventions

  • Fosnetupitant 235 mg solutionDrug

    Fosnetupitant free base 235 mg (corresponding to 260 mg of the chloride hydrochloride salt) in 20 mL ready to use injectable solution for intravenous administration

  • Akynzeo solutionDrug

    235 mg fosnetupitant (corresponding to 260 mg of the chloride hydrochloride salt) / 0.25 mg palonosetron in 20 mL injectable solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study Part A: Number of Treatment-emergent Adverse EventsTime frame: From screening visit (day of informed consent signature) up to 24 h after the investigational medicinal product administration (a maximum of 21 days)
  2. Study Part A: Number of Subjects With Treatment-emergent Adverse EventsTime frame: From screening visit (day of informed consent signature) up to 24 h after the investigational medicinal product administration (a maximum of 21 days)
  3. Study Part A: Type of Treatment-emergent Adverse EventsTime frame: From screening visit (day of informed consent signature) up to 24 h after the investigational medicinal product administration (a maximum of 21 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CROSS Research S.A.

    Arzo, Canton Ticino, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.